The effect of intensive insulin therapy on the insulin-regulatable glucose transporter (GLUT4) expression in skeletal muscle in type 1 diabetes.
Studies in normal man and rodents have demonstrated that the expression of the dominant glucose transporter in skeletal muscle, GLUT4, is regulated by insulin at supraphysiological circulating levels. The present study was designed to determine whether intensified insulin replacement therapy for 24 h given to patients with Type 1 diabetes in poor metabolic control was associated with an adaptive regulation of GLUT4 mRNA and protein levels in vastus lateralis muscle. Nine Type 1 diabetic patients with a mean HbA1c of 10.3% were included in the protocol. After intensified treatment with soluble insulin for 24 h the fasting plasma glucose concentration decreased from 20.8 +/- 2.3 (SD) to 8.7 +/- 2.3 mmol 1-1, whereas the fasting serum insulin level increased from 0.06 +/- 0.02 to 0.17 +/- 0.09 nmol 1-1. However, despite a 2.8-fold increase in serum insulin levels and more than a halving of the plasma glucose concentration for at least 15 h no significant alterations occurred in the amount of GLUT4 protein (0.138 +/- 0.056, poor control vs 0.113 +/- 0.026 arb. units, improved control, p = 0.16) or GLUT4 mRNA (96432 +/- 44985, poor control vs 81395 +/- 25461 arb. units, improved control, p = 0.54). These results suggest, that in spite of evidence that high insulin levels affect GLUT4 expression in muscle, changes in serum insulin within the physiological range do not play a major role in the short-term regulation of GLUT4 expression in Type 1 diabetic patients.
Andersen
P H
PH
Division of Endocrinology and Metabolism, University Clinic of Internal Medicine C, Aarhus Amtssygehus, Denmark.
Vestergaard
H
H
Lund
S
S
Vedel
P
P
Junker
S
S
Kahn
B B
BB
Pedersen
O
O
D000328:Adult; D001706:Biopsy; D001786:Blood Glucose / Q000378:metabolism; D004247:DNA / Q000378:metabolism; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism*; D005260:Female; D051275:Glucose Transporter Type 4; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007328:Insulin / Q000627:therapeutic use*; D008297:Male; D009004:Monosaccharide Transport Proteins / Q000096:biosynthesis / Q000187:drug effects / Q000378:metabolism*; D009124:Muscle Proteins; D009132:Muscles / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D012313:RNA / Q000378:metabolism
D001786:Blood Glucose; D004247:DNA; D051275:Glucose Transporter Type 4; D006442:Glycated Hemoglobin; D007328:Insulin; D009004:Monosaccharide Transport Proteins; D009124:Muscle Proteins; D012313:RNA; C495692:SLC2A4 protein, human